Journal
MOLECULAR & CELLULAR ONCOLOGY
Volume 4, Issue 4, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/23723556.2017.1338208
Keywords
CD49f tumor-initiating cells; chemoresistance; docetaxel; PDX (patient-derived orthoxenografts); triple negative breast cancer (TNBC)
Categories
Funding
- Spanish Ministry of Economy and Competitivity MINECO
- ISCIII - FEDER funds/European Regional Development Fund (ERDF) - a way to build Europe- [SAF2011-22893, SAF2014-55997, PIE13/00022]
- Susan G Komen Foundation [CCR13262449]
- Generalitat de Catalunya
Ask authors/readers for more resources
Taxanes are mainstay treatment of triple negative breast cancer (TNBC) patients but resistance often develops. Using TNBC patient-derived orthoxenografts (PDX) we have recently discovered that a CD49f+ chemoresistant population with tumor-initiating ability is present in sensitive tumors and expands in tumors that have acquired resistance. Importantly, sensitivity to taxanes is recovered after long-term drug interruption. The characterization of this chemoresistant CD49f+ cells provides a unique opportunity to identify novel targets for the treatment of chemoresistant TNBC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available